A Placebo-controlled Trial of Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Among Atherosclerosis Renal-vascular Hypertension Patients

NANot yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 30, 2025

Primary Completion Date

August 30, 2028

Study Completion Date

August 30, 2029

Conditions
Renal Artery Stenosis AtheroscleroticSecondary Hypertension Renal Arterial
Interventions
DIAGNOSTIC_TEST

renal artery fractional flow reserve measurement

Eligible participants who meet all inclusion and exclusion criteria will undergo renal angiography. On the day of angiography, a functional assessment of renal artery stenosis will be performed according to the Standard Operating Procedure (SOP) using a pressure wire under dopamine-induced maximal hyperemia to measure the Fractional Flow Reserve (FFR).

DRUG

dopamine

Administer dopamine at 50 µg/kg via the renal artery to induce hyperemic.

DEVICE

renal artery stent

Stent will be treated for the stenotic renal artery for patients randomized to stenting group

OTHER

sham stenting

For participants randomized to the sham procedure, the procedure will last at least 15 minutes to simulate actual intervention according to SOP guidelines.

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER

NCT07111442 - A Placebo-controlled Trial of Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Among Atherosclerosis Renal-vascular Hypertension Patients | Biotech Hunter | Biotech Hunter